Liquid biopsy in pancreatic cancer: Are we ready to apply it in the clinical practice?
EntidadUAM. Departamento de Medicina
Fecha de edición2021-04-20
CitaCancers 13.8 (2021): 1986
Financiado porThis research received no external funding.
Versión del editorhttps://doi.org/10.3390/cancers13081986
Materiaspancreatic ductal adenocarcinoma; liquid biopsy; ctDNA; exosomes; CTCs; miRNAs; Medicina
Derechos© 2021 by the authors.
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional.
Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to advance in the development of tools that help us in the early diagnosis, treatment selection, disease monitoring, evaluation of the response and prognosis. Liquid biopsy (LB), in its different modalities, represents a particularly interesting tool for these purposes, since it is a minimally invasive and risk-free procedure that can detect both the presence of genetic material from the tumor and circulating tumor cells (CTCs) in the blood and therefore distantly reflect the global status of the disease. In this work we review the current status of the main LB modalities (ctDNA, exosomes, CTCs and cfRNAs) for detecting and monitoring PDAC.
Lista de colecciones del ítem
Mostrando ítems relacionados por título, autor, creador y materia.